The requirement of Artemis in double-strand break repair depends on the type of DNA damage.
暂无分享,去创建一个
H. Koyama | S. Takayama | M. Fujii | D. Ayusawa | N. Adachi | Kensuke Miki | Susumu Iiizumi | Aya Kurosawa
[1] G. Iliakis,et al. Marked dependence on growth state of backup pathways of NHEJ. , 2007, International journal of radiation oncology, biology, physics.
[2] M. Wyatt,et al. Methylating agents and DNA repair responses: Methylated bases and sources of strand breaks. , 2006, Chemical research in toxicology.
[3] L. Povirk. Biochemical mechanisms of chromosomal translocations resulting from DNA double-strand breaks. , 2006, DNA repair.
[4] H. Koyama,et al. Simple one-week method to construct gene-targeting vectors: application to production of human knockout cell lines. , 2006, BioTechniques.
[5] K. Schwarz,et al. Making V(D)J rearrangement visible: quantification of recombination efficiency in real time at the single cell level. , 2006, Journal of immunological methods.
[6] T. Date,et al. 53BP1 contributes to survival of cells irradiated with X‐ray during G1 without Ku70 or Artemis , 2006, Genes to cells : devoted to molecular & cellular mechanisms.
[7] S. Soubeyrand,et al. Artemis phosphorylated by DNA-dependent protein kinase associates preferentially with discrete regions of chromatin. , 2006, Journal of molecular biology.
[8] A. Fischer,et al. Cernunnos Interacts with the XRCC4·DNA-ligase IV Complex and Is Homologous to the Yeast Nonhomologous End-joining Factor Nej1* , 2006, Journal of Biological Chemistry.
[9] S. Jackson,et al. XLF Interacts with the XRCC4-DNA Ligase IV Complex to Promote DNA Nonhomologous End-Joining , 2006, Cell.
[10] Yunmei Ma,et al. The Artemis:DNA-PKcs endonuclease cleaves DNA loops, flaps, and gaps. , 2005, DNA repair.
[11] Yunmei Ma,et al. Repair of Double-Strand DNA Breaks by the Human Nonhomologous DNA End Joining Pathway: The Iterative Processing Model , 2005, Cell cycle.
[12] Yunmei Ma,et al. Plenary Papers (356 articles) , 2005 .
[13] L. Notarangelo,et al. Damaging‐agent sensitivity of Artemis‐deficient cell lines , 2005, European journal of immunology.
[14] A. Feeney,et al. Targeted Disruption of the Artemis Murine Counterpart Results in SCID and Defective V(D)J Recombination That Is Partially Corrected with Bone Marrow Transplantation1 , 2005, The Journal of Immunology.
[15] M. Lieber,et al. Genetic Interactions between BLM and DNA Ligase IV in Human Cells* , 2004, Journal of Biological Chemistry.
[16] Yunmei Ma,et al. A biochemically defined system for mammalian nonhomologous DNA end joining. , 2004, Molecular cell.
[17] H. Arakawa,et al. DNA Cross-Link Repair Protein SNM1A Interacts with PIAS1 in Nuclear Focus Formation , 2004, Molecular and Cellular Biology.
[18] Yunmei Ma,et al. The mechanism of vertebrate nonhomologous DNA end joining and its role in V(D)J recombination. , 2004, DNA repair.
[19] H. Koyama,et al. Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage. , 2004, Biochemical and biophysical research communications.
[20] Yunmei Ma,et al. Functional and biochemical dissection of the structure‐specific nuclease ARTEMIS , 2004, The EMBO journal.
[21] Stephen P. Jackson,et al. A means to a DNA end: the many roles of Ku , 2004, Nature Reviews Molecular Cell Biology.
[22] H. Koyama,et al. Hypersensitivity of Nonhomologous DNA End-joining Mutants to VP-16 and ICRF-193 , 2003, Journal of Biological Chemistry.
[23] George Iliakis,et al. Biochemical evidence for Ku-independent backup pathways of NHEJ. , 2003, Nucleic acids research.
[24] Yunmei Ma,et al. Mechanism and regulation of human non-homologous DNA end-joining , 2003, Nature Reviews Molecular Cell Biology.
[25] M. van der Burg,et al. Radiosensitive SCID patients with Artemis gene mutations show a complete B-cell differentiation arrest at the pre-B-cell receptor checkpoint in bone marrow. , 2003, Blood.
[26] K. Schwarz,et al. The embryonic lethality in DNA ligase IV-deficient mice is rescued by deletion of Ku: implications for unifying the heterogeneous phenotypes of NHEJ mutants. , 2002, DNA repair.
[27] JAMES C. Wang,et al. Cellular roles of DNA topoisomerases: a molecular perspective , 2002, Nature Reviews Molecular Cell Biology.
[28] S. Jackson,et al. Sensing and repairing DNA double-strand breaks. , 2002, Carcinogenesis.
[29] Yunmei Ma,et al. Hairpin Opening and Overhang Processing by an Artemis/DNA-Dependent Protein Kinase Complex in Nonhomologous End Joining and V(D)J Recombination , 2002, Cell.
[30] H. Koyama,et al. DNA ligase IV-deficient cells are more resistant to ionizing radiation in the absence of Ku70: Implications for DNA double-strand break repair , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[31] J. Essigmann,et al. Mechanisms of resistance to cisplatin. , 2001, Mutation research.
[32] H. Koyama,et al. Decreased topoisomerase IIα expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells , 2001 .
[33] A. Fischer,et al. Artemis, a Novel DNA Double-Strand Break Repair/V(D)J Recombination Protein, Is Mutated in Human Severe Combined Immune Deficiency , 2001, Cell.
[34] J. Haber. Partners and pathwaysrepairing a double-strand break. , 2000, Trends in genetics : TIG.
[35] A. Fischer,et al. A new gene involved in DNA double-strand break repair and V(D)J recombination is located on human chromosome 10p. , 2000, Human molecular genetics.
[36] N. Osheroff,et al. A Novel Mechanism of Cell Killing by Anti-topoisomerase II Bisdioxopiperazines* , 2000, The Journal of Biological Chemistry.
[37] B. Hill,et al. Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds , 1999, British Journal of Cancer.
[38] M. Leng,et al. Interstrand cross-links of cisplatin induce striking distortions in DNA. , 1999, Journal of inorganic biochemistry.
[39] C. Cordon-Cardo,et al. Catalytic subunit of DNA-dependent protein kinase: impact on lymphocyte development and tumorigenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[40] J. Hoeijmakers,et al. Molecular mechanisms of DNA double strand break repair. , 1998, Trends in cell biology.
[41] K. Schwarz,et al. DNA ligase IV is essential for V(D)J recombination and DNA double-strand break repair in human precursor lymphocytes. , 1998, Molecular cell.
[42] T. Andoh,et al. Catalytic inhibitors of DNA topoisomerase II. , 1998, Biochimica et biophysica acta.
[43] M. Lieber,et al. Requirement for an Interaction of XRCC4 with DNA Ligase IV for Wild-type V(D)J Recombination and DNA Double-strand Break Repairin Vivo * , 1998, The Journal of Biological Chemistry.
[44] Y. Yamaguchi-Iwai,et al. Homologous recombination and non‐homologous end‐joining pathways of DNA double‐strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells , 1998, The EMBO journal.
[45] P. Jeggo,et al. Targeted disruption of the catalytic subunit of the DNA-PK gene in mice confers severe combined immunodeficiency and radiosensitivity. , 1998, Immunity.
[46] A. Fischer,et al. A Human Severe Combined Immunodeficiency (SCID) Condition with Increased Sensitivity to Ionizing Radiations and Impaired V(D)J Rearrangements Defines a New DNA Recombination/Repair Deficiency , 1998, The Journal of experimental medicine.
[47] G. Chu. Double Strand Break Repair* , 1997, The Journal of Biological Chemistry.
[48] W. Allan,et al. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. , 1997, Biochemical pharmacology.
[49] W. T. Beck,et al. Antitopoisomerase drug action and resistance. , 1996, European journal of cancer.
[50] Z. Wang,et al. Differential control of transcription‐induced and overall DNA supercoiling by eukaryotic topoisomerases in vitro. , 1996, The EMBO journal.
[51] J. Wang,et al. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[52] H. Pinedo,et al. Mechanism of action of antitumor drug etoposide: a review. , 1988, Journal of the National Cancer Institute.
[53] B. Hill,et al. Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents , 1998, Cancer Chemotherapy and Pharmacology.
[54] L. Liu,et al. DNA topoisomerase poisons as antitumor drugs. , 1989, Annual review of biochemistry.